Abstract:Interest has been recently rekindled in short chain fatty acids (SCFAs) with the emergence of prebiotics and probiotics aimed at improving colonic and systemic health. Dietary carbohydrates, specifically resistant starches and dietary fiber, are substrates for fermentation that produce SCFAs, primarily acetate, propionate, and butyrate, as end products. The rate and amount of SCFA production depends on the species and amounts of microflora present in the colon, the substrate source and gut transit time. SCFAs are readily absorbed. Butyrate is the major energy source for colonocytes. Propionate is largely taken up by the liver. Acetate enters the peripheral circulation to be metabolized by peripheral tissues. Specific SCFA may reduce the risk of developing gastrointestinal disorders, cancer, and cardiovascular disease. Acetate is the principal SCFA in the colon, and after absorption it has been shown to increase cholesterol synthesis. However, propionate, a gluconeogenerator, has been shown to inhibit cholesterol synthesis. Therefore, substrates that can decrease the acetate: propionate ratio may reduce serum lipids and possibly cardiovascular disease risk. Butyrate has been studied for its role in nourishing the colonic mucosa and in the prevention of cancer of the colon, by promoting cell differentiation, cell-cycle arrest and apoptosis of transformed colonocytes; inhibiting the enzyme histone deacetylase and decreasing the transformation of primary to secondary bile acids as a result of colonic acidification. Therefore, a greater increase in SCFA production and potentially a greater delivery of SCFA, specifically butyrate, to the distal colon may result in a protective effect. Butyrate irrigation (enema) has also been suggested in the treatment of colitis. More human studies are now needed, especially, given the diverse nature of carbohydrate substrates and the SCFA patterns resulting from their fermentation. Short-term and long-term human studies are particularly required on SCFAs in relation to markers of cancer risk. These studies will be key to the success of dietary recommendations to maximize colonic disease prevention.

Short chain fatty acids in human gut and metabolic health

Short-Chain Fatty Acids Modulate Healthy Gut Microbiota Composition and Functional Potential

Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism

Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications

Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health

Short-chain fatty acids in control of body weight and insulin sensitivity

Gut microbiota derived short-chain fatty acids in physiology and pathology: An update

Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota

Diet, Microbiome, and Inflammation Predictors of Fecal and Plasma Short-Chain Fatty Acids in Humans

The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome

The role of short-chain fatty acids in health and disease

Colonic Health: Fermentation and Short Chain Fatty Acids

The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism

Microbial Regulation of Host Physiology by Short-chain Fatty Acids

Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans

SCFA: mechanisms and functional importance in the gut

Towards microbial fermentation metabolites as markers for health benefits of prebiotics

The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health

The role of short-chain fatty acids in microbiota–gut–brain communication

From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course?

Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health